July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Real world results of aflibercept treatment for macular oedema secondary to central retinal vein occlusions
Author Affiliations & Notes
  • Zaria Ali
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Tariq Mehmood Aslam
    University of Manchester, Manchester, United Kingdom
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Caroline Bailey
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Ramandeep Chhabra
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Amy Stone
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Yvonne D'Souza
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Sajjad Mahmood
    Manchester Royal Eye Hospital, Blackburn, ENGLAND, United Kingdom
  • Konstantinos Balaskas
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    University of Manchester, Manchester, United Kingdom
  • Footnotes
    Commercial Relationships   Zaria Ali, None; Tariq Aslam, Bausch and lomb (C), Bausch and lomb (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R), Oraya (C), Oraya (R), Thea Pharmaceuticals (C), Thea Pharmaceuticals (R); Caroline Bailey, None; Ramandeep Chhabra, None; Amy Stone, None; Yvonne D'Souza, None; Sajjad Mahmood, None; Konstantinos Balaskas, Bayer (R), Novartis (R), Novartis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5441. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zaria Ali, Tariq Mehmood Aslam, Caroline Bailey, Ramandeep Chhabra, Amy Stone, Yvonne D'Souza, Sajjad Mahmood, Konstantinos Balaskas; Real world results of aflibercept treatment for macular oedema secondary to central retinal vein occlusions. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5441.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Macular oedema (MO) secondary to central retinal vein occlusions (CRVO) is one of the most common indications for anti-VEGF treatment. We present real world results of patients with MO secondary to CRVO treated with Aflibercept with either a treat and extend (T+E) or pro re nata (PRN) regimen.

Methods : A retrospective cohort study was carried out. Records of patients attending for anti-VEGF treatment between January 2011 and June 2017 were reviewed. Inclusion criteria was treatment naieve patients diagnosed with MO secondary to CRVO undergoing treatment with aflibercept for a minimum of 6 months. Exclusion criteria included co-existing retinal pathology. Patients were split into two groups; those who underwent T+E and those who underwent PRN treatment. Electronic records were reviewed and data for patient demographics, and baseline, 6 month and 12 months visual acuity (VA) and central macular thickness (CMT) was recorded.

Results : 38 patients were included. Mean age was 70.0 years (SD 13.2). Male to female ratio was 13:25. 16 patients were in the T+E group, and 22 in the PRN group. Mean number of visits per year in the T+E group was 5.7 (SD 1.5) and 10.2 (SD 2.5) in the PRN group which was statistically significant (p < 0.001). Mean number of injections per year in the T+E group was 7.2 (SD 1.8) and 7.5 (SD 2.9) in the PRN group. There was no statistical significance between the two groups (p=0.86). There was no difference in baseline VA between the two groups (p=0.94) or baseline CMT (p=0.62). In the T+E group change in VA from baseline at 6 months was 25.4 letters (SD 19.9), and at 12 months 18.2 letters (SD 33.5). In the PRN group change in VA from baseline at 6 months was 13.7 letters (SD 19.5) and at 12 months 16.0 letters (SD 16.5). There is no statistical difference in change in VA at 6 months (p =0.13) or at 12 months (p =0.44). In the T+E group change in CMT from baseline at 6 months was -307.25 (SD 93.7) and at 12 months -261.7 (SD 169.1). In the PRN group change in CMT from baseline at 6 months was -203.0 (SD 205.4) and at 12 months -248.8 (SD 269.8). There is a statistical difference in change in CMT at 6 months (p=0.09) but not at 12 months (p=0.9) between the two groups.

Conclusions : Treatment with Aflibercept in patients with MO secondary to CRVO using a T+E regimen has comparable outcomes to PRN treatment but with significantly lower number of mean visits per year.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×